Table 1.
Baseline characteristics of the patients.
| Characteristics | T (n=38) | TL (n=45) | TLT (n=66) | P |
|---|---|---|---|---|
| Age (years) | 56.5 ± 13.0 | 56.6 ± 12.1 | 55.8 ± 11.2 | 0.940 |
| Sex | 0.974 | |||
| Male | 35 (92.1) | 42 (93.3) | 61 (92.4) | |
| Female | 3 (7.9) | 3 (6.7) | 5 (7.6) | |
| Etiology | 0.474 | |||
| Hepatitis B virus | 34 (89.5) | 36 (80.0) | 54 (81.8) | |
| Others | 4 (10.5) | 9 (20.0) | 12 (18.2) | |
| Child-Pugh class | 0.716 | |||
| A | 32 (84.2) | 40 (88.9) | 59 (89.4) | |
| B | 6 (15.8) | 5 (11.1) | 7 (10.6) | |
| Cirrhosis | 0.982 | |||
| Yes | 31 (81.6) | 36 (80.0) | 53 (80.3) | |
| No | 7 (18.4) | 9 (20.0) | 13 (19.7) | |
| Tumor size (cm) | 5.9 (4.9-8.1) | 5.8 (3.1-8.0) | 6.0 (3.9-8.4) | 0.613 |
| >7 | 23 (60.5) | 27 (60.0) | 41 (62.1) | 0.972 |
| ≤7 | 15 (39.5) | 18 (40.0) | 25 (37.9) | |
| Number of lesions | 0.967 | |||
| >3 | 34 (89.5) | 40 (88.9) | 58 (87.9) | |
| 2-3 | 4 (10.5) | 5 (11.1) | 8 (12.1) | |
| AFP (ng/mL) | 0.257 | |||
| <400 | 22 (57.9) | 28 (62.2) | 48 (72.7) | |
| ≥400 | 16 (42.1) | 17 (37.8) | 18 (27.3) | |
| Sessions of TACE | 6 (4-11) | 4 (1-8) | 3 (1-6) | 0.059 |
T, TACE, transarterial chemoembolization; TL, TACE combined with lenvatinib; TLT, TACE combined with lenvatinib and tislelizumab; AFP, α-fetoprotein.